RxDoctor Payments Data

Venice Sanchez, MD

Psychiatry · Newport Beach, CANPI 1609004837

Payments from drug & device makers

$15,180in general payments, 2019–2025

Across 845 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • USWM, LLC$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Alkermes, Inc.$974
  • Sunovion Pharmaceuticals Inc.$888
  • plus $6K from 34 others

What the payments were for

  • Food & beverage$14,65297%
  • Education$210%
  • Gifts$5063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,180 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$49,313
Medicare patients
41
Services billed
467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole26$48,576
TrintellixVortioxetine Hydrobromide35$17,817
Aripiprazole36$7,401
Dextroamphetamine Sulfate18$2,558
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$1,972
Lurasidone Hcl32$1,873
Duloxetine Hcl64$1,807
Bupropion XlBupropion Hcl62$1,306
Doxepin Hcl19$982
Quetiapine Fumarate61$860
Oxcarbazepine13$736
Bupropion Hcl SrBupropion Hcl25$698
Buspirone Hcl58$688
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl26$637
Trazodone Hcl43$632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$1,746$48,57626 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$513$17,81735 claims
Lilly USA, LLCOlanzapine$19$42035 claims
Almatica Pharma LLCSertraline Hcl$22$30441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →